Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 –
